ClinicalTrials.gg
CompletedNCT05901987Updated Nov 17, 2026

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

A Phase 1/2 interventional study of GC101 in SMA II, sponsored by GeneCradle Inc. Completed at 5 sites in China. Open to participants aged 6 Months to 60 Months. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GeneCradle Inc · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
6 Months to 60 Months
Sex
All
01

Study summary

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 2 (SMA 2) patients.

Read the detailed description

The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 2 patients. Open-label, dose-escalation clinical trial of GC101 will be conducted in multiple centers in China.

GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up on various time points.

The primary analysis for efficacy will be assessed at 12 months after treatment with GC101 on the motor milestone of stand unassisted for at least 3 seconds for patients of age between 6 and 24 months, or changes from baseline HFMSE scores for patients of age between 24 and 60 months.

02

Conditions studied

03

In context

Spinal Muscular Atrophies of Childhood

61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.

This study's enrollment of 29 is above the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.

Browse Spinal Muscular Atrophies of Childhood studies →

Lead sponsor

GeneCradle Inc is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 60 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 6 months and 60 months of age on day of signing form;
  • Patient with SMA Type 2 as defined by the following features:

    • Diagnosis of SMA based on gene mutation analysis with bi-allelic SMN1 mutations (deletion or point mutations) and 2 copies of SMN
    • Onset of disease between 6 and 18 months of age
  • Patient who can sit alone but never be able to stand or walk alone ;
  • The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Patient who has participated in any previous gene therapy research trials;
  • Patient who has received Nusinersen within 4 months and Risdiplam within 15 days before treatment;
  • Patient who has AAV9 neutralizing antibody titer ≥1:200;
  • Patient with a point mutation in SMN2 (c.859G>C);
  • Patient who requires non-invasive ventilatory support averaging≥12 hours/day at screening, or use invasive ventilatory support or pulse oximetry \< 95% saturation while awake and calm at screening;
  • Patient who is positive for (HIV) antibody, surface antigen, antibody, or treponema pallidum antibody;
  • Abnormal laboratory values considered , including gamma-glutamyl transferase(GGT), (AST), alanine aminotransferase (ALT), > 3x (ULN), (Hgb)\< 110 or >150 g/L, \<lower limit of normal (LLN);Class IV patient based on Modified Ross Heart Failure Classification for Children;
  • Patient with a history of allergy;
  • that would interfere with the lumbar puncture procedures;
  • Presence of an untreated active infection requiring systemic antiviral therapy at any time during the screening period;
  • Vaccination less than 2 weeks before infusion of vector;
  • Patient who has any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study.

Note: Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Low dosing group

    1.2x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)

    Genetic: GC101

  • Experimental
    Medium dosing group

    2.4x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)

    Genetic: GC101

  • Experimental
    High dosing group

    4.8x10\^14 vg/person of GC101 delivered one-time intrathecally (n=3)

    Genetic: GC101

Interventions

  • GeneticGC101

    Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests

    Time frame: 52 weeks

  2. Proportion of patients who can stand unassisted for at least 3 seconds at Month 12

    Time frame: 52 weeks

  3. Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12

    HFMSE consists of 33 activities that can be scored one of three ways: 0 for unable to perform, 1 for performs with modification/adaptation, and 2 for performs without modification.

    Time frame: 52 weeks

Secondary outcomes

  1. Proportion of patients treated with GC101 who achieve motor milestone of walk alone for 5 steps at Month 12

    Time frame: 52 weeks

Other outcomes

  1. Change from baseline in independent ventilatory support time at Month 12

    Time frame: 52 weeks

  2. Number of patients whose HFMSE scores improve more than 3 at Month 12

    Time frame: 52 weeks

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2023 to primary completion in Apr 2025, 20 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Dec 2025, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2023
First posted
Jun 13, 2023
StartActual
Aug 1, 2023
Primary completionActual
Apr 22, 2025
CompletionActual
Dec 31, 2025was Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 17, 2026
Study completion
Dec 2028→Dec 31, 2025 (actual)
Nov 17, 2026
Enrollment
33 (estimated)→29 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Completed
    Study completion Dec 2028→Dec 31, 2025 (now actual)
    Enrollment 33 (estimated)→29 (actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05901987
Lead sponsor
GeneCradle Inc
Responsible party
Sponsor
First posted
Jun 13, 2023
Start date
Aug 1, 2023
Primary completion
Apr 22, 2025
Completion
Dec 31, 2025
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion